Curaleaf (OTCMKTS:CURLF – Get Free Report) and Profound Medical (NASDAQ:PROF – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.
Institutional & Insider Ownership
0.0% of Curaleaf shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Curaleaf and Profound Medical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Curaleaf | $1.27 billion | 1.56 | -$231.07 million | ($0.04) | -211.75 |
| Profound Medical | $23.63 million | 11.74 | -$42.57 million | ($0.93) | -8.14 |
Profound Medical has lower revenue, but higher earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Curaleaf and Profound Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Curaleaf | -0.76% | 0.43% | 0.13% |
| Profound Medical | -137.51% | -59.57% | -47.87% |
Risk & Volatility
Curaleaf has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Curaleaf and Profound Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Curaleaf | 0 | 1 | 2 | 1 | 3.00 |
| Profound Medical | 1 | 0 | 1 | 1 | 2.67 |
Curaleaf presently has a consensus price target of $6.00, suggesting a potential downside of 29.16%. Profound Medical has a consensus price target of $11.50, suggesting a potential upside of 51.92%. Given Profound Medical’s higher probable upside, analysts clearly believe Profound Medical is more favorable than Curaleaf.
Summary
Curaleaf beats Profound Medical on 8 of the 14 factors compared between the two stocks.
About Curaleaf
Curaleaf Holdings, Inc. is a cannabis company that cultivates, processes and sells cannabis products for medical and adult-use markets. Its products include cannabis flower, pre-rolls, concentrates, vapes, edibles, tinctures and topical products, sold under brands including Curaleaf, Select and Grassroots. The company operates across multiple U.S. markets through cultivation and processing facilities, wholesale operations and retail dispensaries. Through Curaleaf International, it also serves medical cannabis markets in Europe and other international markets.
About Profound Medical
Profound Medical Corp. is a medical-technology company focused on developing and commercializing minimally invasive, incision-free treatments for prostate disease. The company’s flagship platform, TULSA-PRO, combines magnetic resonance imaging (MRI) with robotic-controlled transurethral ultrasound to ablate targeted prostate tissue while enabling physicians to monitor treatment in real time. TULSA-PRO is primarily used for the treatment of localized prostate cancer and other prostate conditions, including benign prostatic hyperplasia.
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
